Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (324)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05685004 | Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) | active not recruiting | Phase 2 / Phase 3 | 120 | TVAX BiomedicalINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05864534 | Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 25 | Northwestern UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05871021 | Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma(PRIDE) | active not recruiting | Phase 2 | 107 | University Hospital TuebingenOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04729959 | Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma | active not recruiting | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03197506 | Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | active not recruiting | Phase 2 | 52 | Mayo ClinicOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02974621 | Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02704858 | Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | active not recruiting | Phase 1 / Phase 2 | 49 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03212274 | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations | active not recruiting | Phase 2 | 89 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02981940 | A Study of Abemaciclib in Recurrent Glioblastoma | active not recruiting | Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT02337686 | Pembrolizumab in Treating Patients With Recurrent Glioblastoma | active not recruiting | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04677049 | Study of Niacin in Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 59 | AHS Cancer Control AlbertaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04145115 | A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden | active not recruiting | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 2 | Aug 31, 2026 | clinicaltrials |
| NCT02179086 | Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 624 | NRG OncologyOTHER | 2 | Aug 28, 2026 | clinicaltrials |
| NCT05039281 | Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05463848 | Surgical Pembro +/- Olaparib w TMZ for rGBM | active not recruiting | Phase 2 | 52 | L. Nicolas Gonzalez Castro, MD, PhDOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03113500 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | active not recruiting | Phase 2 | 48 | City of Hope Medical CenterOTHER | 2 | Aug 21, 2026 | clinicaltrials |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04469075 | Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields | active not recruiting | Phase 2 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT02455557 | SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 66 | Roswell Park Cancer InstituteOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT01837862 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | active not recruiting | Phase 1 / Phase 2 | 10 | Julie KrystalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03862430 | A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM(RESTORE) | active not recruiting | Phase 2 | 87 | NuvOx LLCINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT02152982 | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | active not recruiting | Phase 2 / Phase 3 | 447 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT05781321 | Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study | active not recruiting | Phase 2 | 170 | Mayo ClinicOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03180502 | Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma | active not recruiting | Phase 2 | 120 | NRG OncologyOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT01352520 | SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) | active not recruiting | Phase 2 | 79 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03541902 | Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma | active not recruiting | Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03581292 | Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations | active not recruiting | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 5 | Jul 16, 2026 | clinicaltrials |
| NCT03744793 | Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer | active not recruiting | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03919071 | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma | active not recruiting | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2026 | clinicaltrials |
| NCT04485949 | A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma | active not recruiting | Phase 2 | 99 | ImvaxINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06061809 | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | active not recruiting | Phase 2 | 34 | ImmunityBio, Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02177578 | Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme | active not recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05120284 | Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) | active not recruiting | Phase 2 | 40 | University of FloridaOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06157541 | T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma(TCaP) | active not recruiting | Phase 1 / Phase 2 | 58 | Queensland Institute of Medical ResearchOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04225039 | Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma | active not recruiting | Phase 2 | 39 | University of PennsylvaniaOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05053880 | A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme | active not recruiting | Phase 1 / Phase 2 | 48 | Accendatech USA Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02649582 | Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients(ADDIT-GLIO) | active not recruiting | Phase 1 / Phase 2 | 20 | University Hospital, AntwerpOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03688178 | DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab(DERIVe) | active not recruiting | Phase 2 | 43 | Annick Desjardins, MDOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05736406 | A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 12 | Hemerion TherapeuticsINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT02331498 | Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme(PAZOGLIO) | active not recruiting | Phase 1 / Phase 2 | 51 | Centre Antoine LacassagneOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03491683 | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | active not recruiting | Phase 1 / Phase 2 | 52 | Inovio PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT04922723 | Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma(PRIDE) | active not recruiting | Phase 1 / Phase 2 | 16 | West Virginia UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05565521 | UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly(UNITED2) | active not recruiting | Phase 2 | 55 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06336291 | A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence(GLIOSTELLA) | active not recruiting | Phase 2 | 90 | Philogen S.p.A.INDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04762069 | A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme | active not recruiting | Phase 2 | 252 | CNS Pharmaceuticals, Inc.INDUSTRY | 5 | Apr 15, 2026 | clinicaltrials |
| NCT04528680 | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma(SC9/ABX) | active not recruiting | Phase 1 / Phase 2 | 57 | Northwestern UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05808608 | A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 37 | Hao ZengOTHER | 1 | Apr 7, 2026 | clinicaltrials |
Data updated 10 hours agoSource updated Sep 29, 2026source: clinicaltrials